Download - Drug Resistance in TB
![Page 1: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/1.jpg)
G u i d e d b y,
M r. S . G . P a t i l
D e p t . o f P h a r m a c e u t i c s
S c h o o l o f P h a r m a c y, S . R . T. M . U . N a n d e d
Seminar onDRUG RESISTANCE TUBERCULOSIS
P r e s e n t e d b y,
M r. R a v i k a n t V. K a d a m
D e p t . o f P h a r m a c e u t i c s
S c h o o l o f P h a r m a c y, S . R . T. M . U . N a n d e d
![Page 2: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/2.jpg)
Contents
IntroductionTransmission of TBPathogenesis of TBDrug-Resistant TB (MDR and XDR)Factors that Create ResistanceTreatment Special Situations
![Page 3: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/3.jpg)
Introduction
It is mainly caused by Mycobacterium tuberculosis Tuberculosis is an ancient disease & it remains the leading cause of death of
human being.
![Page 4: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/4.jpg)
USAID Report on Tuberculosis in India
India has more new tuberculosis (TB) cases annually than any other country, ranking first among the 22 high-burden TB countries worldwide, according to the World Health Organization’s (WHO’s) Global TB Report 2009. TB remains one of the leading infectious causes of mortality in India, causing more than 331,000 deaths in 2007. There were approximately 1.96 million new TB cases in India in 2007, representing more than 21 percent of all TB cases worldwide
![Page 5: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/5.jpg)
Transmission of TB
M. tuberculosis is carried in airborne particles, called droplet nuclei, of 1– 5 microns in diameter.
Infectious droplet nuclei are generated when persons who have pulmonary or laryngeal TB disease cough, sneeze, shout, or sing. Depending on the environment, these tiny particles can remain suspended in the air for several hours.
M. tuberculosis is transmitted through the air, not by surface contact. Transmission occurs when a person inhales droplet nuclei containing M. tuberculosis, and the droplet nuclei traverse the mouth or nasal passages, upper respiratory tract, and bronchi to reach the alveoli of the lungs
![Page 6: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/6.jpg)
Transmission of TB
![Page 7: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/7.jpg)
Pathogenesis of TB
Infection occurs when a person inhales droplet nuclei containing tubercle bacilli that reach the alveoli of the lungs.
These tubercle bacilli are ingested by alveolar macrophages; the majority of these bacilli are destroyed or inhibited.
A small number may multiply intracellularly and are released when the macrophages die. If alive, these bacilli may spread by way of lymphatic channels or through the bloodstream to more distant tissues and organs (including areas of the body in which TB disease is most likely to develop: regional lymph nodes, apex of the lung, kidneys, brain, and bone).
This process of dissemination primes the immune system for a systemic response.
![Page 8: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/8.jpg)
Pathogenesis of TB
Droplet nuclei containing tubercle bacilli are inhaled, enter the lungs, and travel to the alveoli.
![Page 9: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/9.jpg)
Pathogenesis of TB
Tubercle bacilli multiply in the alveoli.
![Page 10: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/10.jpg)
Pathogenesis of TB
A small number of tubercle bacilli enter the bloodstream and spread throughout the body.
The tubercle bacilli may reach any part of the body, including areas where TB disease is more likely to develop (such as the brain, larynx, lymph node, lung, spine, bone, or kidney).
![Page 11: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/11.jpg)
Pathogenesis of TB
Within 2 to 8 weeks, special immune cells called macrophages ingest and surround the tubercle bacilli. The cells form a barrier shell, called a granuloma, that keeps the bacilli contained and under control (LTBI).
![Page 12: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/12.jpg)
Pathogenesis of TB
If the immune system cannot keep the tubercle bacilli under control, the bacilli begin to multiply rapidly (TB disease). This process can occur in different areas in the body, such as the lungs, kidneys, brain, or bone
![Page 13: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/13.jpg)
Drug-Resistant TB
Drug-resistant TB is caused by M. tuberculosis organisms that are resistant to the drugs normally used to treat the disease . Drug-resistant TB is transmitted in the same way as drug-susceptible TB, and is no more infectious than drug-susceptible TB. However, delay in the recognition of drug resistance or prolonged periods of infectiousness may facilitate increased transmission and further development of drug resistance.
![Page 14: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/14.jpg)
Drug-Resistant TB
Drug resistant TB Mono resistance Poly resistance Multi Drug Resistant TB(MDR- TB) Extensive Drug Resistant TB (XDR-TB) Total Drug Resistance (TDR – TB)
![Page 15: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/15.jpg)
Drug-Resistant TB
Mono Drug Resistance (Resistance to single first line ATT)
Poly Drug Resistance (Resistance to two or more first line ATT except MDR-TB)
![Page 16: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/16.jpg)
Drug-Resistant TB
Multi-drug resistant tuberculosis (MDR TB) is defined as resistance to isoniazid and Rifampicin (a laboratory diagnosis).
Extensively drug resistant TB (XDR-TB) is MDR + resistance to any fluoroquinolone + resistance to at least one 2nd-line injectable drug (amikacin, kanamycin, or capreomycin
![Page 17: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/17.jpg)
TDR: Total Drug Resistance
Resistance to all first-line anti-TB drugs (FLD) and second-line anti-TB drugs (SLD) that were tested.
![Page 18: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/18.jpg)
Drug-Resistant TB
![Page 19: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/19.jpg)
EPIDEMIOLOGY
In our country
![Page 20: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/20.jpg)
Global Data
![Page 21: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/21.jpg)
MECHANISMS & FACTORS
![Page 22: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/22.jpg)
![Page 23: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/23.jpg)
Mechanism of resistance
INH Chromosomally mediated Loss of catalase/peroxidase Mutation in mycolic acid synthesis Regulators of peroxide respo
![Page 24: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/24.jpg)
Mechanism of resistance
Rifampin Reduced binding to RNA polymerase
Clusters of mutations at “Rifampin Resistance Determining Region” (RRDR)
Reduced Cell wall permeability
![Page 25: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/25.jpg)
Gene location associated Drug-Resistant M.tuberculosis
Drug Gene
Isoniazid Kat G, Inh A, Kas A
Rifampicin rpo B
Ethambutol emb B
Streptomycin rps L
Pyrazinamide pnc A
Fluoroquinolones gyr A
![Page 26: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/26.jpg)
FACTORS RESPONSIBLE FOR DEVELOPMENT OF DRUG RESISTANCE
CLINICAL / OPERATIONAL FACTORS Unreliable treatment regimen by doctors
Lesser number of drugs Inadequate dosage / duration
Addition of a single drug in failing regimen
Easy availability of drugs in private sector
Poor drug supply
Poor quality of drugs : poor bioavailability
![Page 27: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/27.jpg)
FACTORS RESPONSIBLE FOR DEVELOPMENT OF DRUG RESISTANCE
BIOLOGICAL FACTORS :
Initial bacillary population
Local factors in host favourable for multiplication of bacilli
Presence of drug in insufficient concentration
![Page 28: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/28.jpg)
FACTORS RESPONSIBLE FOR DEVELOPMENT OF DRUG RESISTANCE
SOCIOLOGICAL FACTORS :
Irregular intake inadequate duration Neglect of disease Ignorance
![Page 29: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/29.jpg)
Genesis of MDR TB
Resistance is a man-made amplification of a natural phenomenon. i.e. Selection & proliferation of pre existing mutants due to man made factors leads to drug resistance.
Inadequate drug delivery is main cause of secondary drug resistance.
Secondary drug resistance is the main cause of primary drug resistance due to transmission of resistant strains.
MDR due to spontaneous mutations is not possible as the genes encoding resistance for anti TB are unlinked.
![Page 30: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/30.jpg)
Treatment…
The choice of drugs would be based on: • The pattern of drug resistance • Which drugs have been taken previously • Whether the patient has underlying medical conditions • The adverse effects associated with the drug
![Page 31: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/31.jpg)
Drugs in MDR TB Management
Less efficacious and poorly tolerated
Most efficacious and best tolerated
![Page 32: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/32.jpg)
Important principles of MDR-TB regimen design
1. Use at least 4 reliable drugs .2. Do not use drugs with cross resistance .3. Eliminate drugs that are not safe for the patient.4. Include drugs from Groups 1-5 in a hierarchical order.5. Monitor and manage adverse effects of drugs. 6. Never add a single drug to failing regime.
![Page 33: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/33.jpg)
General Treatment Principles
Provide 18-24 months’ treatment, always with intensive phase of at least 6 months ( current WHO guidelines -8 months).
Provide DOT therapy.Warn patients about possible side-effects.Manage side-effects appropriately.Perform cultures monthly.
![Page 34: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/34.jpg)
Regimen under DOTS Plus Programme in India (PMDT)
INITIAL INTENSIVE PHASE : 6- 9 months Inj. Kanamycin Tab Ethionamide Tab Ofloxacin Tab. Pyrazinamide Tab. Ethambutol Cap Cycloserine CONTINUATION PHASE : 18 months Tab Ethionamide Tab Ofloxacin Tab Ethambutol Cap Cycloserine
![Page 35: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/35.jpg)
DOTS PLUS DAILY REGIME
![Page 36: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/36.jpg)
Nausea and vomiting - Eto, PAS, Z, EGiddiness - Aminoglycosides, Eto, Fq and/or ZOcular toxicity - ERenal toxicity - AminoglycosidesArthralgia - Z and/or FqCutaneous reactions - pruritis or rash- any of the drugs
used.Hepatitis - Z & Eto
![Page 37: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/37.jpg)
![Page 38: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/38.jpg)
References
Sharma SK, Mohan A. Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuber-culosis control. Chest 2006; 130(1):261-272.
Andrews J, Basu S, Scales D, Smith-Rohrberg Maru D, Subbaraman R. XDR-TB in South Africa: theory and practice. PLoS Med 2007; 4(4): e163.doi:10.1371/journal.pmed.0040163.
Nature Volume 469 issue 7331 2011 [doi 10.1038%2Fnature09657] Koul, Anil; Arnoult, Eric; Lounis, Nacer; Guillemont, Jerome; An -- The challenge of new drug discovery for tuberculosis.sssss
Nature Reviews Drug Discovery Volume 12 issue 5 2013 [doi 10.1038%2Fnrd4001] Zumla, Alimuddin; Nahid, Payam; Cole, Stewart T. -- Advances in the development of new tuberculosis drugs.
![Page 39: Drug Resistance in TB](https://reader030.vdocuments.pub/reader030/viewer/2022020116/55cf1162bb61eb20368b46bc/html5/thumbnails/39.jpg)
THANK YOU…………..!